Since the commercialization of the first CAR-T cell therapies, these revolutionary treatments have reshaped the landscape of cancer therapy, offering unprecedented hope to patients with hematologic malignancies. In this webinar transcript, which was hosted on Cell & Gene Therapy Insights, experts discuss commercialization strategies and manufacturing technology in advancing CAR-T cell therapies to market.
In this podcast episode, OmniaBio discusses the innovative advancements in cell and gene therapy, focusing on how AI, automation, and robotics are revolutionizing manufacturing processes by reducing costs, increasing production capacity, and ultimately, improving patient outcomes in the rapidly evolving cell and gene therapy field.
In this webinar, we will delve into a detailed case study showcasing our work conducting design of experiments (DoE) to optimize LVV stability.
As CAR-T cell therapies continue to lead innovation and revolutionize disease treatment, with several approved CAR-T cell therapies and many more advancing through the clinical pipeline, the significance of effective tech transfer is undeniable. In this webinar, learn from our speakers' past experiences as they define the core principles of a successful CAR-T tech transfer and more.
As the number of iPSC-based therapies in clinical development is increasing, the industry is seeing significant advancement following decades of the industry’s iPSC development efforts. In this webinar transcript, which was hosted on Cell & Gene Therapy Insights in March 2024, industry experts delve into the critical aspects of reshaping the future landscape of iPSC-based therapies.
Since the commercialization of the first CAR-T cell therapies, these revolutionary treatments have reshaped the landscape of cancer therapy, offering unprecedented hope to patients with hematologic malignancies. Listen to the panel of industry and healthcare sector experts discuss the critical intersection of commercialization strategies and manufacturing technology in advancing the next wave of CAR-T cell therapies to market.
